130 related articles for article (PubMed ID: 35123773)
21. Melanoma of the Vulva and Vagina: Surgical Management and Outcomes Based on a Clinicopathologic Reviewof 68 Cases.
Sinasac SE; Petrella TM; Rouzbahman M; Sade S; Ghazarian D; Vicus D
J Obstet Gynaecol Can; 2019 Jun; 41(6):762-771. PubMed ID: 30391279
[TBL] [Abstract][Full Text] [Related]
22. Malignant melanoma of the vulva and vagina. Trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960-1984.
Ragnarsson-Olding B; Johansson H; Rutqvist LE; Ringborg U
Cancer; 1993 Mar; 71(5):1893-7. PubMed ID: 8448754
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB; Pecora AL; Jaslowski AJ; Cohen GI; Kuzel TM; Lao CD; Kirkwood JM
Cancer; 2017 Jul; 123(14):2688-2697. PubMed ID: 28334439
[TBL] [Abstract][Full Text] [Related]
24. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Kron A; Alidousty C; Scheffler M; Merkelbach-Bruse S; Seidel D; Riedel R; Ihle MA; Michels S; Nogova L; Fassunke J; Heydt C; Kron F; Ueckeroth F; Serke M; Krüger S; Grohe C; Koschel D; Benedikter J; Kaminsky B; Schaaf B; Braess J; Sebastian M; Kambartel KO; Thomas R; Zander T; Schultheis AM; Büttner R; Wolf J
Ann Oncol; 2018 Oct; 29(10):2068-2075. PubMed ID: 30165392
[TBL] [Abstract][Full Text] [Related]
25. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
[TBL] [Abstract][Full Text] [Related]
26. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
Siroy AE; Boland GM; Milton DR; Roszik J; Frankian S; Malke J; Haydu L; Prieto VG; Tetzlaff M; Ivan D; Wang WL; Torres-Cabala C; Curry J; Roy-Chowdhuri S; Broaddus R; Rashid A; Stewart J; Gershenwald JE; Amaria RN; Patel SP; Papadopoulos NE; Bedikian A; Hwu WJ; Hwu P; Diab A; Woodman SE; Aldape KD; Luthra R; Patel KP; Shaw KR; Mills GB; Mendelsohn J; Meric-Bernstam F; Kim KB; Routbort MJ; Lazar AJ; Davies MA
J Invest Dermatol; 2015 Feb; 135(2):508-515. PubMed ID: 25148578
[TBL] [Abstract][Full Text] [Related]
27. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
Berns EM; van Staveren IL; Look MP; Smid M; Klijn JG; Foekens JA
Br J Cancer; 1998 Apr; 77(7):1130-6. PubMed ID: 9569050
[TBL] [Abstract][Full Text] [Related]
28. A Retrospective Review of Conjunctival Melanoma Presentation, Treatment, and Outcome and an Investigation of Features Associated With BRAF Mutations.
Larsen AC; Dahmcke CM; Dahl C; Siersma VD; Toft PB; Coupland SE; Prause JU; Guldberg P; Heegaard S
JAMA Ophthalmol; 2015 Nov; 133(11):1295-303. PubMed ID: 26425792
[TBL] [Abstract][Full Text] [Related]
29. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
30. Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey.
Mikkelsen LH; Larsen AC; von Buchwald C; Drzewiecki KT; Prause JU; Heegaard S
APMIS; 2016 Jun; 124(6):475-86. PubMed ID: 27004972
[TBL] [Abstract][Full Text] [Related]
31. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.
Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S
Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467
[TBL] [Abstract][Full Text] [Related]
32. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
33. Melanoma of the Vagina: Case Report and Systematic Review of the Literature.
Rapi V; Dogan A; Schultheis B; Hartmann F; Rezniczek GA; Tempfer CB
Anticancer Res; 2017 Dec; 37(12):6911-6920. PubMed ID: 29187473
[TBL] [Abstract][Full Text] [Related]
34. Primary malignant melanoma of the vagina: a retrospective clinicopathologic study of 44 cases.
Xia L; Han D; Yang W; Li J; Chuang L; Wu X
Int J Gynecol Cancer; 2014 Jan; 24(1):149-55. PubMed ID: 24362720
[TBL] [Abstract][Full Text] [Related]
35. Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study.
van Zeijl MCT; Boer FL; van Poelgeest MIE; van den Eertwegh AJM; Wouters MWJM; de Wreede LC; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; Boers-Sonderen MJ; Kapiteijn EHW; Haanen JBAG
Eur J Cancer; 2020 Sep; 137():127-135. PubMed ID: 32763783
[TBL] [Abstract][Full Text] [Related]
36. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
[TBL] [Abstract][Full Text] [Related]
37. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract][Full Text] [Related]
38. Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment.
Byeon S; Cho HJ; Jang KT; Kwon M; Lee J; Lee J; Kim ST
ESMO Open; 2021 Feb; 6(1):100002. PubMed ID: 33399091
[TBL] [Abstract][Full Text] [Related]
39. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract][Full Text] [Related]
40. Malignant melanoma of the female genital tract. A report of nine cases in the Chinese of Hong Kong.
Khoo US; Collins RJ; Ngan HY
Pathology; 1991 Oct; 23(4):312-7. PubMed ID: 1784522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
